First Horizon Advisors, Inc. Novo Cure LTD Transaction History

First Horizon Advisors, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$67.99 - $89.57 $203 - $268	-3 Reduced 1.21%	244 $17,000
Q2 2022 Aug 02, 2022	BUY	$56.6 - $89.9 $13,980 - $22,205	247 New	247 $17,000
Q1 2022 May 10, 2022	SELL	$60.15 - $84.52 $16,300 - $22,904	-271 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$75.08 - $121.99 $675 - $1,097	9 Added 3.44%	271 $20,000
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $15,682 - $26,264	135 Added 106.3%	262 $30,000
Q3 2021 Nov 09, 2021	SELL	$116.17 - $194.55 $14,521 - $24,318	-125 Reduced 49.6%	127 $14,000
Q2 2021 Aug 09, 2021	SELL	$130.4 - $225.58 $5,216 - $9,023	-40 Reduced 13.7%	252 $55,000
Q1 2021 May 11, 2021	SELL	$124.11 - $190.17 $3,350 - $5,134	-27 Reduced 8.46%	292 $38,000
Q4 2020 Feb 11, 2021	BUY	$112.16 - $174.14 $3,028 - $4,701	27 Added 9.25%	319 $55,000
Q3 2020 Nov 12, 2020	SELL	$58.05 - $111.31 $8,301 - $15,917	-143 Reduced 32.87%	292 $32,000
Q1 2020 May 05, 2020	BUY	$57.05 - $95.75 $17,286 - $29,012	303 Added 229.55%	435 $29,000
Q4 2019 Jan 07, 2020	BUY	$68.3 - $93.8 $9,015 - $12,381	132 New	132 $11,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.07B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.